Navigation Links
Dyadic International Announces Date and Time of Third Quarter 2011 Financial Results Release and Conference Call
Date:10/20/2011

JUPITER, Fla., Oct. 20, 2011 /PRNewswire/ -- Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company, today announced that it will report its financial results for the third quarter ended September 30, 2011 and will host a conference call to discuss those financial results as follows:

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO)

Financial Results Release:  After market close, Thursday, November 3, 2011.

Conference Call:  5:00 p.m. Eastern Time, Thursday, November 3, 2011.

In order to participate in the live conference call, please use the following dial-in numbers five to ten minutes prior to start time:

Calling from the United States or Canada:  888-661-5176.

Calling from other countries:  913-312-0702.

Please reference Passcode:  3489907.

A replay of the conference call will be available on the Dyadic website (www.dyadic.com) shortly after the live event.

About Dyadic

Dyadic is a global biotechnology company that uses its patented and proprietary technologies for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, biopharmaceutical and industrial enzyme industries.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dyadic International Raises $3 Million in Private Placement of Convertible Notes
2. Dyadic International Reports 2011 Second Quarter Financial Results
3. Dyadic International Announces Date of Second Quarter 2011 Financial Results Release and Conference Call
4. Dyadic International Enters Into Research and License Agreement With Major Player in the Animal Feed Industry
5. Dyadic to Present at the World Congress on Industrial Biotechnology & Bioprocessing
6. Dyadic Netherlands Enters Into R&D Collaboration With Sanofi Pasteur and EnGen Bio
7. New U.S. Patent Issued to Dyadic International
8. Dyadic International to Present at Advanced Biofuels Leadership Conference
9. Dyadic International Introduces Advanced Biofuels Enzyme AlternaFuel® CMAX™ At World Biofuels Markets
10. Dyadic International Reports 2010 Fiscal Year Financial Results
11. Dyadic International Launches High Performance Enzyme for Pulp and Paper Industry Using New C1 Production Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Fla. , Feb. 16, 2017  MDNA ... revolutionizing the development of liquid biopsy tests based ... entered into an exclusive license agreement with its ... MDNA,s proprietary liquid biopsy test for prostate cancer, ... South Korea . This is the first ...
(Date:2/16/2017)... Mass. , Feb. 16, 2017   Biostage, ... the "Company"), a biotechnology company developing bioengineered organ implants ... esophagus, bronchus and trachea, announced today the closing on ... of 20,000,000 shares of common stock and warrants to ... proceeds of $8.0 million. The offering was priced at ...
(Date:2/16/2017)... Feb. 16, 2017  Champions Oncology, Inc. (NASDAQ: ... and sale of advanced technology solutions and products to ... announced the addition of new cohorts of PDX models ... models will expand Champions, product line in hepatocellular cancer, ... cancer, AML, and non-small cell lung cancer (including EGFR ...
(Date:2/16/2017)... and NEW YORK , Feb. ... near completion of their $7M Series B financing, adding ... of the $3.5M led by Mesa Verde Venture Partners ... These resources will be directed towards further accelerating commercial ... a comprehensive genomic profiling test and expanding the Paradigm ...
Breaking Biology Technology:
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... NEW YORK , Feb. 8, 2017 /PRNewswire/ ... an individual,s voice to match it against a ... voice such as pitch, cadence, and tone are ... systems require minimal hardware installation, as most PCs ... remotely for different transactions. Voice recognition biometrics are ...
Breaking Biology News(10 mins):